Join Us | Contact Us | Sitemap | Korean

      About Us | Report | Custom Research | Support


Login

Category

Telecom/Wireless

Electronic

Digital Devices/Media/Broadcasting

Information Technology

Energy

Life Science

Chemical/Advanced Materials

Automotive

Environment

Consumer Goods

Marketing/Advertising

Finance

Construction

Transportation

Consumer Survey

Defence/Aerospace

Food/Beverage

Heavy Industry

Education

Industrial Machinery

International Trades

Sports/Leisure

Marine/Ship Building

Fashion

Government/Policy

Industrial Arts/Jewellery

Company Profiles

ETC

 
Location : HOME > Report > Life Science > Pharmaceuticals
Investigation Report on China Imipenem and cilastatin sodium Market, 2010-2019
Publisher China Research and Intelligence
Date 2015-06
Quantity 30 pages
Type Report
Price

Print

Description

Coming into being in the 1980s, penem is an unsatured ¥â-lactam featuring broad spectrum, strong effect and low resistance rate. Actually it is the most potent antibiotic with the broadest antibacterial spectrum hitherto. And Imipenem cilastatin is one of the commercially available penem class.
Developed by Merck & Sharp Dohme (US) in 1979, imipenem and cilastatin sodium is the most famous one in imipenem cilastatin class. Its sales value around the world was USD 610 million in 2011 and USD 520 million in 2012, down 25.4% year-on-year. And imipenem and cilastatin sodium is used for the treatment of mixed infection caused by a variety of pathogens and aerobic or anaerobic bacteria as well as the early treatment before pathogens are identified.
Imipenem and cilastatin sodium develops fast after entering China with annual sales value rising from less than CNY 200 million in 2005 to CNY 595 million in 2014 and CAGR during this period reaching 15.6%. Currently, imipenem and cilastatin sodium in the Chinese market mainly come from the following companies: Merck & Sharp Dohme (US), United Laboratories, RANBAXY LABORATORIES LTD(ID) and Shenzhen Haibin Pharmaceutical Co., Ltd, among which Merck & Sharp Dohme (US) has the largest market share of 90% for sales value in 2014.
As the development programs and manufacturers of penem antibiotics increase, the market competition will become more and more severe in future. The market size of imipenem and cilastatin sodium is expected to keep expanding in the next few years in China.

Readers can get at least the following information from this report:

-market size of imipenem and cilastatin sodium in China
-competitive landscape of imipenem and cilastatin sodium in Chinese market
-price of imipenem and cilastatin sodium made by different enterprises in China
-market outlook of imipenem and cilastatin sodium in China

The author suggests the following groups of people purchase this report:

-manufacturers of anti-infective drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service


About Us | Privacy Polocy | Terms & Conditions | Delivery/Payment

Samwon Bldg., 210-1 Nonhyun-dong, Gangnam-gu, 135-996, Seoul, Korea | LNH, Inc.
Tel : 82-2-554-0001 / Fax : 82-2-3444-5501 / E-mail : sales@landh.co.kr
Copyright ¨Ï 2008 LNH, Inc. All rights reserved.